Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials
Titel:
Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials
Auteur:
Donohue, James F. Feldman, Gregory Sethi, Sanjay Barnes, Chris N. Pendyala, Srikanth Bourdet, David Crater, Glenn